The Marlborough, Mass.-based company said that it plans to offer $850 million in 3.45% notes due 2024, $850 million in 3.75% notes due 2026, $850 million in 4% notes due 2029, $750 million in 4.55% notes due 2039 and $1 billion in 4.7% notes due 2049.
Funds will also be used to redeem outstanding notes, including 6% notes due January 2020 and 2.85% notes due May 2020, and to repay amounts outstanding from its $1 billion term loan facility set to mature in August 2019.
Boston Scientific said that it expects the offering to close on February 25.
Earlier this month, the U.S. Federal Trade Commission requested more information about the proposed $4 billion tie-up of BTG and Boston Scientific, but the companies said they still expect the merger to close on schedule in mid-2019.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.